CRBUCaribou Biosciences, Inc.

$181M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+232.0% YoY

Gross Profit

-$12M-298.1% margin

Operating Income

-$19M-468.1% margin

Net Income

-$21M-527.4% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

+169.4%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$935,000

Balance Sheet

Total Assets

$462M

Total Liabilities

$58M

Stockholders' Equity

$404M

Cash & Equivalents

$435M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$1M	+232.0%
Gross Profit	-$12M	$1M	-1089.6%
Operating Income	-$19M	-$8M	-126.2%
Net Income	-$21M	-$8M	-164.4%

Geographic Segments

UNITED STATES

$4M88%

Non Us

$470,00012%

CRBU Q3 2021 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena